Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Current Assets: 2009-2025

Historic Current Assets for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $85.7 million.

  • Lifecore Biomedical's Current Assets rose 5.73% to $85.7 million in Q2 2025 from the same period last year, while for May 2025 it was $85.7 million, marking a year-over-year increase of 5.73%. This contributed to the annual value of $85.7 million for FY2025, which is 5.73% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Current Assets is $85.7 million, which was up 1.74% from $84.2 million recorded in Q1 2025.
  • Lifecore Biomedical's Current Assets' 5-year high stood at $158.3 million during Q1 2021, with a 5-year trough of $74.2 million in Q3 2024.
  • Over the past 3 years, Lifecore Biomedical's median Current Assets value was $82.3 million (recorded in 2023), while the average stood at $82.0 million.
  • In the last 5 years, Lifecore Biomedical's Current Assets tumbled by 35.58% in 2023 and then rose by 10.58% in 2025.
  • Over the past 5 years, Lifecore Biomedical's Current Assets (Quarterly) stood at $150.6 million in 2021, then decreased by 20.90% to $119.1 million in 2022, then crashed by 35.58% to $76.7 million in 2023, then increased by 6.71% to $81.9 million in 2024, then rose by 5.73% to $85.7 million in 2025.
  • Its Current Assets stands at $85.7 million for Q2 2025, versus $84.2 million for Q1 2025 and $81.9 million for Q4 2024.